NewAmsterdam Pharma (NAMS) Common Equity (2021 - 2026)

NewAmsterdam Pharma has reported Common Equity for 6 years, with the latest figure at $665.2 million in Q1 2026.

• Quarterly Common Equity fell 14.43% year-over-year to $665.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $665.2 million (down 14.43% YoY) and the FY2025 annual result came in at $683.4 million, down 9.78% from the prior year.
• Common Equity eased to $665.2 million in Q1 2026 per NAMS's latest filing, from $683.4 million in the prior quarter.
• Over five years, Common Equity peaked at $778.5 million in Q2 2025 and troughed at $288.4 million in Q4 2023.
• A 5-year average of $532.5 million and a median of $453.1 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity surged 767.87% in 2022, then plunged 41.66% in 2023.
• Over 5 years, Common Equity stood at $494.3 million in 2022, then slumped by 41.66% to $288.4 million in 2023, then surged by 162.66% to $757.5 million in 2024, then slipped by 9.78% to $683.4 million in 2025, then fell by 2.66% to $665.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $665.2 million, $683.4 million, and $728.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.